inos polyclonal antibody Search Results


94
Bioss inducible nitric oxide synthase
Inducible Nitric Oxide Synthase, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/inos+polyclonal+antibody/10__48048_slash_tis__2026__12876-55-16-23?v=Bioss
Average 94 stars, based on 1 article reviews
inducible nitric oxide synthase - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier

90
OriGene inos
Figure 3. Representative immunohistochemical stainings for apoptotic markers (TUNEL assay, AAC) and other markers (GSTP1, <t>iNOS,</t> CD31) in pediatric naso- pharyngeal carcinoma. The TUNEL assay stained the nuclei of apoptotic cells. AAC, GSTP1 and iNOS immunostaining was localized in the cytoplasm. CD31 stained tumor blood vessels and weak CD31 immunostaining was also observed outside the vessels in tumor cells. Magnification, x40. TUNEL, terminal deoxy- nucleotidyl transferase dUTP nick-end labelling; AAC, ATP-ADP translocase; GSTP1, glutathione S-transferase π 1; iNOS, inducible nitric oxide synthetase.
Inos, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/inos+polyclonal+antibody/pm30066889-70-7-15?v=OriGene
Average 90 stars, based on 1 article reviews
inos - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
OriGene anti inos
Figure 3. Representative immunohistochemical stainings for apoptotic markers (TUNEL assay, AAC) and other markers (GSTP1, <t>iNOS,</t> CD31) in pediatric naso- pharyngeal carcinoma. The TUNEL assay stained the nuclei of apoptotic cells. AAC, GSTP1 and iNOS immunostaining was localized in the cytoplasm. CD31 stained tumor blood vessels and weak CD31 immunostaining was also observed outside the vessels in tumor cells. Magnification, x40. TUNEL, terminal deoxy- nucleotidyl transferase dUTP nick-end labelling; AAC, ATP-ADP translocase; GSTP1, glutathione S-transferase π 1; iNOS, inducible nitric oxide synthetase.
Anti Inos, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/inos+polyclonal+antibody/arxiv__1608__08565-204-34-47?v=OriGene
Average 90 stars, based on 1 article reviews
anti inos - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

92
OriGene antibodies against phospho nos2 tyr151
Fig. 1. Hydroxyurea induces <t>NOS2</t> expression in erythroid cells. a) Immunocytochemistry for NOS2 protein in HEL92.1.7 cells treated with the indicated con centrations of hydroxyurea (HU) or vehicle (Ctrl) and quantification of NOS2-positive cells. b) Western blot analysis for NOS2 protein in HEL92.1.7 cells treated for 48 h with the indicated concentrations of HU or vehicle (Ctrl). Quantification of band intensity is shown, with β-actin used as a loading control and normalized to Ctrl. c) Western blot for phospho-NFκB p65 (Ser536) and total NFκB p65. d) Western blot for phospho-p38 and total p38. e) Western blot for phospho-ERK1/2 and total ERK1/2, with β-actin, on HEL92.1.7 cells treated with 100 μM HU for 5, 15, or 30 min, or vehicle (Ctrl). Quantification of band intensity is expressed as the phospho-to-total protein ratio and normalized to vehicle-treated cells. f) Western blot for NOS2 protein in HEL92.1.7 cells treated with the indicated concentrations of HU and/or 10 μM of JSH23 for 48 h. Quantification of band intensity is shown with β-actin used as a loading control and normalized to Ctrl. n = 3; mean + SEM, *p < 0.05, **p < 0.01, ***p < 0.001 vs. Ctrl or as indicated.
Antibodies Against Phospho Nos2 Tyr151, supplied by OriGene, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/inos+polyclonal+antibody/pm39615166-58-7-12?v=OriGene
Average 92 stars, based on 1 article reviews
antibodies against phospho nos2 tyr151 - by Bioz Stars, 2026-07
92/100 stars
  Buy from Supplier

94
Bioss rabbit anti inos polyclonal antibody
Fig. 1. Hydroxyurea induces <t>NOS2</t> expression in erythroid cells. a) Immunocytochemistry for NOS2 protein in HEL92.1.7 cells treated with the indicated con centrations of hydroxyurea (HU) or vehicle (Ctrl) and quantification of NOS2-positive cells. b) Western blot analysis for NOS2 protein in HEL92.1.7 cells treated for 48 h with the indicated concentrations of HU or vehicle (Ctrl). Quantification of band intensity is shown, with β-actin used as a loading control and normalized to Ctrl. c) Western blot for phospho-NFκB p65 (Ser536) and total NFκB p65. d) Western blot for phospho-p38 and total p38. e) Western blot for phospho-ERK1/2 and total ERK1/2, with β-actin, on HEL92.1.7 cells treated with 100 μM HU for 5, 15, or 30 min, or vehicle (Ctrl). Quantification of band intensity is expressed as the phospho-to-total protein ratio and normalized to vehicle-treated cells. f) Western blot for NOS2 protein in HEL92.1.7 cells treated with the indicated concentrations of HU and/or 10 μM of JSH23 for 48 h. Quantification of band intensity is shown with β-actin used as a loading control and normalized to Ctrl. n = 3; mean + SEM, *p < 0.05, **p < 0.01, ***p < 0.001 vs. Ctrl or as indicated.
Rabbit Anti Inos Polyclonal Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/inos+polyclonal+antibody/pm37375351-320-4-16?v=Bioss
Average 94 stars, based on 1 article reviews
rabbit anti inos polyclonal antibody - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier

94
Bioss antibodies for inos
Fig. 1. Hydroxyurea induces <t>NOS2</t> expression in erythroid cells. a) Immunocytochemistry for NOS2 protein in HEL92.1.7 cells treated with the indicated con centrations of hydroxyurea (HU) or vehicle (Ctrl) and quantification of NOS2-positive cells. b) Western blot analysis for NOS2 protein in HEL92.1.7 cells treated for 48 h with the indicated concentrations of HU or vehicle (Ctrl). Quantification of band intensity is shown, with β-actin used as a loading control and normalized to Ctrl. c) Western blot for phospho-NFκB p65 (Ser536) and total NFκB p65. d) Western blot for phospho-p38 and total p38. e) Western blot for phospho-ERK1/2 and total ERK1/2, with β-actin, on HEL92.1.7 cells treated with 100 μM HU for 5, 15, or 30 min, or vehicle (Ctrl). Quantification of band intensity is expressed as the phospho-to-total protein ratio and normalized to vehicle-treated cells. f) Western blot for NOS2 protein in HEL92.1.7 cells treated with the indicated concentrations of HU and/or 10 μM of JSH23 for 48 h. Quantification of band intensity is shown with β-actin used as a loading control and normalized to Ctrl. n = 3; mean + SEM, *p < 0.05, **p < 0.01, ***p < 0.001 vs. Ctrl or as indicated.
Antibodies For Inos, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/inos+polyclonal+antibody/10__1080_slash_23311932__2025__2568198-78-25-30?v=Bioss
Average 94 stars, based on 1 article reviews
antibodies for inos - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier

r pe  (Bioss)
94
Bioss r pe
Fig. 1. Hydroxyurea induces <t>NOS2</t> expression in erythroid cells. a) Immunocytochemistry for NOS2 protein in HEL92.1.7 cells treated with the indicated con centrations of hydroxyurea (HU) or vehicle (Ctrl) and quantification of NOS2-positive cells. b) Western blot analysis for NOS2 protein in HEL92.1.7 cells treated for 48 h with the indicated concentrations of HU or vehicle (Ctrl). Quantification of band intensity is shown, with β-actin used as a loading control and normalized to Ctrl. c) Western blot for phospho-NFκB p65 (Ser536) and total NFκB p65. d) Western blot for phospho-p38 and total p38. e) Western blot for phospho-ERK1/2 and total ERK1/2, with β-actin, on HEL92.1.7 cells treated with 100 μM HU for 5, 15, or 30 min, or vehicle (Ctrl). Quantification of band intensity is expressed as the phospho-to-total protein ratio and normalized to vehicle-treated cells. f) Western blot for NOS2 protein in HEL92.1.7 cells treated with the indicated concentrations of HU and/or 10 μM of JSH23 for 48 h. Quantification of band intensity is shown with β-actin used as a loading control and normalized to Ctrl. n = 3; mean + SEM, *p < 0.05, **p < 0.01, ***p < 0.001 vs. Ctrl or as indicated.
R Pe, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/inos+polyclonal+antibody/10__1016_slash_j__psj__2025__105397-68-22-24?v=Bioss
Average 94 stars, based on 1 article reviews
r pe - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier

93
Cusabio batch no csb pa003464
Fig. 1. Hydroxyurea induces <t>NOS2</t> expression in erythroid cells. a) Immunocytochemistry for NOS2 protein in HEL92.1.7 cells treated with the indicated con centrations of hydroxyurea (HU) or vehicle (Ctrl) and quantification of NOS2-positive cells. b) Western blot analysis for NOS2 protein in HEL92.1.7 cells treated for 48 h with the indicated concentrations of HU or vehicle (Ctrl). Quantification of band intensity is shown, with β-actin used as a loading control and normalized to Ctrl. c) Western blot for phospho-NFκB p65 (Ser536) and total NFκB p65. d) Western blot for phospho-p38 and total p38. e) Western blot for phospho-ERK1/2 and total ERK1/2, with β-actin, on HEL92.1.7 cells treated with 100 μM HU for 5, 15, or 30 min, or vehicle (Ctrl). Quantification of band intensity is expressed as the phospho-to-total protein ratio and normalized to vehicle-treated cells. f) Western blot for NOS2 protein in HEL92.1.7 cells treated with the indicated concentrations of HU and/or 10 μM of JSH23 for 48 h. Quantification of band intensity is shown with β-actin used as a loading control and normalized to Ctrl. n = 3; mean + SEM, *p < 0.05, **p < 0.01, ***p < 0.001 vs. Ctrl or as indicated.
Batch No Csb Pa003464, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/inos+polyclonal+antibody/pmc11589485-93-217-216?v=Cusabio
Average 93 stars, based on 1 article reviews
batch no csb pa003464 - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

90
Bioss anti inos solution
Fig. 1. Hydroxyurea induces <t>NOS2</t> expression in erythroid cells. a) Immunocytochemistry for NOS2 protein in HEL92.1.7 cells treated with the indicated con centrations of hydroxyurea (HU) or vehicle (Ctrl) and quantification of NOS2-positive cells. b) Western blot analysis for NOS2 protein in HEL92.1.7 cells treated for 48 h with the indicated concentrations of HU or vehicle (Ctrl). Quantification of band intensity is shown, with β-actin used as a loading control and normalized to Ctrl. c) Western blot for phospho-NFκB p65 (Ser536) and total NFκB p65. d) Western blot for phospho-p38 and total p38. e) Western blot for phospho-ERK1/2 and total ERK1/2, with β-actin, on HEL92.1.7 cells treated with 100 μM HU for 5, 15, or 30 min, or vehicle (Ctrl). Quantification of band intensity is expressed as the phospho-to-total protein ratio and normalized to vehicle-treated cells. f) Western blot for NOS2 protein in HEL92.1.7 cells treated with the indicated concentrations of HU and/or 10 μM of JSH23 for 48 h. Quantification of band intensity is shown with β-actin used as a loading control and normalized to Ctrl. n = 3; mean + SEM, *p < 0.05, **p < 0.01, ***p < 0.001 vs. Ctrl or as indicated.
Anti Inos Solution, supplied by Bioss, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/inos+polyclonal+antibody/pm29263936-70-8-12?v=Bioss
Average 90 stars, based on 1 article reviews
anti inos solution - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

91
Bioss antibodies inos
Histological and immunohistochemical analyses of the synovium. ( A ) Hematoxylin and Eosin staining. Images were taken at 100×. ( B ) Immunohistochemistry results for <t>iNOS</t> <t>and</t> <t>CD206.</t> ( C ) Immunohistochemistry results for IL-1β. Graphs show the results of the synovial lining cell layer and the ratio of the positive cells to the total cells for each protein at four and eight weeks after transplantation. Asterisk indicates a statistically significant difference. Grading of enlargement of the synovial lining cell layer was based on the method of previous report . Scale bars = 100 µm.
Antibodies Inos, supplied by Bioss, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/inos+polyclonal+antibody/pmc08509129-93-18-22?v=Bioss
Average 91 stars, based on 1 article reviews
antibodies inos - by Bioz Stars, 2026-07
91/100 stars
  Buy from Supplier

90
Becton Dickinson polyclonal antibody against inos
Histological and immunohistochemical analyses of the synovium. ( A ) Hematoxylin and Eosin staining. Images were taken at 100×. ( B ) Immunohistochemistry results for <t>iNOS</t> <t>and</t> <t>CD206.</t> ( C ) Immunohistochemistry results for IL-1β. Graphs show the results of the synovial lining cell layer and the ratio of the positive cells to the total cells for each protein at four and eight weeks after transplantation. Asterisk indicates a statistically significant difference. Grading of enlargement of the synovial lining cell layer was based on the method of previous report . Scale bars = 100 µm.
Polyclonal Antibody Against Inos, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/inos+polyclonal+antibody/pmc03487387-51-1-7?v=Becton+Dickinson
Average 90 stars, based on 1 article reviews
polyclonal antibody against inos - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


Figure 3. Representative immunohistochemical stainings for apoptotic markers (TUNEL assay, AAC) and other markers (GSTP1, iNOS, CD31) in pediatric naso- pharyngeal carcinoma. The TUNEL assay stained the nuclei of apoptotic cells. AAC, GSTP1 and iNOS immunostaining was localized in the cytoplasm. CD31 stained tumor blood vessels and weak CD31 immunostaining was also observed outside the vessels in tumor cells. Magnification, x40. TUNEL, terminal deoxy- nucleotidyl transferase dUTP nick-end labelling; AAC, ATP-ADP translocase; GSTP1, glutathione S-transferase π 1; iNOS, inducible nitric oxide synthetase.

Journal: International journal of oncology

Article Title: Identification of fatal outcome in a childhood nasopharyngeal carcinoma patient by protein expression profiling.

doi: 10.3892/ijo.2018.4491

Figure Lengend Snippet: Figure 3. Representative immunohistochemical stainings for apoptotic markers (TUNEL assay, AAC) and other markers (GSTP1, iNOS, CD31) in pediatric naso- pharyngeal carcinoma. The TUNEL assay stained the nuclei of apoptotic cells. AAC, GSTP1 and iNOS immunostaining was localized in the cytoplasm. CD31 stained tumor blood vessels and weak CD31 immunostaining was also observed outside the vessels in tumor cells. Magnification, x40. TUNEL, terminal deoxy- nucleotidyl transferase dUTP nick-end labelling; AAC, ATP-ADP translocase; GSTP1, glutathione S-transferase π 1; iNOS, inducible nitric oxide synthetase.

Article Snippet: Primary antibodies used in immunohistochemistry staining were: iNOS (1:150; clone K13-A; cat. no. DB 003-0.05; Acris Antibodies; OriGene Technologies, Inc., Rockville, MD, USA), p53 (1:100; clone Y5; cat. no. MA5-14467; Thermo Fisher Scientific, Inc., Waltham, MA, USA), Ki-67 (1:200; clone SP6; cat. no. ab16667; Abcam, Cambridge, UK), c-Myc (1:50; clone 9E10.3; cat. no. AHO0062), CD31 (1:150; clone JC/70A; cat. no. MA5-13188), CD56 (1:100; clone 56C04; cat. no. MA5-11563), CD8 (1:50; clone SP16; cat. no. MA5-14548), CD4 (1:10; clone 4B12; cat. no. MA5-12259) (all from Thermo Fisher Scientific, Inc.), AAC (1:50 polyclonal; cat. no. 51031-1-AP; ProteinTech Group, Inc., Chicago, IL, USA), GSTP1 (1:1,500; clone 3F2C2; cat. no. LS-B1576-50; Acris Antibodies; OriGene Technologies, Inc.), WT1 (1:10; clone 6F-H2; cat. no. MA1-46028; Thermo Fisher Scientific, Inc.), 14-3-3-τ (1:100; clone AT1A1; cat. no. AM09060PU-N; Acris Antibodies; OriGene Technologies, Inc.), E6 (1:50; clone C1P5; cat. no. MA1-46057; Thermo Fisher Scientific, Inc.) and E7 (1:100; clone TVG701Y; cat. no. MA5-14132; Thermo Fisher Scientific, Inc.).

Techniques: Immunohistochemical staining, TUNEL Assay, Staining, Immunostaining

Fig. 1. Hydroxyurea induces NOS2 expression in erythroid cells. a) Immunocytochemistry for NOS2 protein in HEL92.1.7 cells treated with the indicated con centrations of hydroxyurea (HU) or vehicle (Ctrl) and quantification of NOS2-positive cells. b) Western blot analysis for NOS2 protein in HEL92.1.7 cells treated for 48 h with the indicated concentrations of HU or vehicle (Ctrl). Quantification of band intensity is shown, with β-actin used as a loading control and normalized to Ctrl. c) Western blot for phospho-NFκB p65 (Ser536) and total NFκB p65. d) Western blot for phospho-p38 and total p38. e) Western blot for phospho-ERK1/2 and total ERK1/2, with β-actin, on HEL92.1.7 cells treated with 100 μM HU for 5, 15, or 30 min, or vehicle (Ctrl). Quantification of band intensity is expressed as the phospho-to-total protein ratio and normalized to vehicle-treated cells. f) Western blot for NOS2 protein in HEL92.1.7 cells treated with the indicated concentrations of HU and/or 10 μM of JSH23 for 48 h. Quantification of band intensity is shown with β-actin used as a loading control and normalized to Ctrl. n = 3; mean + SEM, *p < 0.05, **p < 0.01, ***p < 0.001 vs. Ctrl or as indicated.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Article Title: Hydroxyurea inhibits proliferation and stimulates apoptosis through inducible nitric oxide synthase in erythroid cells.

doi: 10.1016/j.biopha.2024.117723

Figure Lengend Snippet: Fig. 1. Hydroxyurea induces NOS2 expression in erythroid cells. a) Immunocytochemistry for NOS2 protein in HEL92.1.7 cells treated with the indicated con centrations of hydroxyurea (HU) or vehicle (Ctrl) and quantification of NOS2-positive cells. b) Western blot analysis for NOS2 protein in HEL92.1.7 cells treated for 48 h with the indicated concentrations of HU or vehicle (Ctrl). Quantification of band intensity is shown, with β-actin used as a loading control and normalized to Ctrl. c) Western blot for phospho-NFκB p65 (Ser536) and total NFκB p65. d) Western blot for phospho-p38 and total p38. e) Western blot for phospho-ERK1/2 and total ERK1/2, with β-actin, on HEL92.1.7 cells treated with 100 μM HU for 5, 15, or 30 min, or vehicle (Ctrl). Quantification of band intensity is expressed as the phospho-to-total protein ratio and normalized to vehicle-treated cells. f) Western blot for NOS2 protein in HEL92.1.7 cells treated with the indicated concentrations of HU and/or 10 μM of JSH23 for 48 h. Quantification of band intensity is shown with β-actin used as a loading control and normalized to Ctrl. n = 3; mean + SEM, *p < 0.05, **p < 0.01, ***p < 0.001 vs. Ctrl or as indicated.

Article Snippet: Membranes were incubated overnight at 4◦C with antibodies against phospho-NOS2 (Tyr151) (TA325739, OriGene, Rockville, Maryland, USA), NOS2 (E-AB-64331, Elabscience, Houston, Texas, USA), phosphorylated NFκB p65 (p-NFκB p65) (Ser536) (3031, Cell Signaling, Danvers, Massachusetts, USA), total NFκB p65 (E-AB-22066, Elabscience), phospho-p38 (Tyr180/Tyr182) (E-AB-21027, Elabscience), total p38 (E-AB-66279, Elabscience), phospho-p44/42 (extracellular signal-regulated kinase 1⁄2 [Erk1/2]) (Thr202/Tyr204) (9101, Cell Signaling), total p44/42 (Erk1/2) (9102, Cell Signaling), or β-actin (MAB8928, R&D Systems, Minneapolis, Minnesota, USA).

Techniques: Expressing, Immunocytochemistry, Western Blot, Control

Fig. 2. Hydroxyurea directly activates NOS2 in vitro. (a) Nitrite concentration in HEL92.1.7 cells treated with vehicle (Ctrl), HU, L-NAME, 1400W, or a combination of HU and L-NAME or 1400W. (b) Citrulline concentration in HEL92.1.7 cells treated with vehicle (Ctrl), HU, L-NAME, or a combination of HU and L-NAME. c) Western blot for phospho-NOS2 (Tyr151) and total NOS2 protein in HEL92.1.7 cells treated with the indicated concentrations of HU or vehicle (Ctrl). Quantification of band intensity is expressed as the phospho-NOS2 to total NOS2 ratio and normalized to vehicle-treated cells. d) Nitrite concentration in in vitro NOS enzymatic assays with the indicated concentrations of HU and incubation times. e) Citrulline concentration in in vitro NOS enzymatic assays with the indicated concentrations of HU and incubation times. f) In silico model of HU and NOS2 interaction showing binding at amino acids ASP382, ASP385, and ARG388, and with the substrate L- arginine (ARG700). g) Molecular dynamics analysis showing root mean square deviation (RMSD) of the C–Cα–N backbone versus simulation time for NOS2 in complex with and without HU during 20 ns. h) Root mean square fluctuation (RMSF) values of the NOS2-HU complex plotted against residue numbers. j) Radius of gyration (Rg) plots of NOS2 receptor with and without HU in active sites during 20 ns. a-e) n = 3; mean + SEM, *p < 0.05, **p < 0.01, ***p < 0.001 vs. Ctrl or 0.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Article Title: Hydroxyurea inhibits proliferation and stimulates apoptosis through inducible nitric oxide synthase in erythroid cells.

doi: 10.1016/j.biopha.2024.117723

Figure Lengend Snippet: Fig. 2. Hydroxyurea directly activates NOS2 in vitro. (a) Nitrite concentration in HEL92.1.7 cells treated with vehicle (Ctrl), HU, L-NAME, 1400W, or a combination of HU and L-NAME or 1400W. (b) Citrulline concentration in HEL92.1.7 cells treated with vehicle (Ctrl), HU, L-NAME, or a combination of HU and L-NAME. c) Western blot for phospho-NOS2 (Tyr151) and total NOS2 protein in HEL92.1.7 cells treated with the indicated concentrations of HU or vehicle (Ctrl). Quantification of band intensity is expressed as the phospho-NOS2 to total NOS2 ratio and normalized to vehicle-treated cells. d) Nitrite concentration in in vitro NOS enzymatic assays with the indicated concentrations of HU and incubation times. e) Citrulline concentration in in vitro NOS enzymatic assays with the indicated concentrations of HU and incubation times. f) In silico model of HU and NOS2 interaction showing binding at amino acids ASP382, ASP385, and ARG388, and with the substrate L- arginine (ARG700). g) Molecular dynamics analysis showing root mean square deviation (RMSD) of the C–Cα–N backbone versus simulation time for NOS2 in complex with and without HU during 20 ns. h) Root mean square fluctuation (RMSF) values of the NOS2-HU complex plotted against residue numbers. j) Radius of gyration (Rg) plots of NOS2 receptor with and without HU in active sites during 20 ns. a-e) n = 3; mean + SEM, *p < 0.05, **p < 0.01, ***p < 0.001 vs. Ctrl or 0.

Article Snippet: Membranes were incubated overnight at 4◦C with antibodies against phospho-NOS2 (Tyr151) (TA325739, OriGene, Rockville, Maryland, USA), NOS2 (E-AB-64331, Elabscience, Houston, Texas, USA), phosphorylated NFκB p65 (p-NFκB p65) (Ser536) (3031, Cell Signaling, Danvers, Massachusetts, USA), total NFκB p65 (E-AB-22066, Elabscience), phospho-p38 (Tyr180/Tyr182) (E-AB-21027, Elabscience), total p38 (E-AB-66279, Elabscience), phospho-p44/42 (extracellular signal-regulated kinase 1⁄2 [Erk1/2]) (Thr202/Tyr204) (9101, Cell Signaling), total p44/42 (Erk1/2) (9102, Cell Signaling), or β-actin (MAB8928, R&D Systems, Minneapolis, Minnesota, USA).

Techniques: In Vitro, Concentration Assay, Western Blot, Incubation, In Silico, Binding Assay, Residue

Fig. 3. NOS2 inhibition or knockdown prevents HU-induced inhibition of HEL92.1.7 cell proliferation. HEL92.1.7 cells were treated with the indicated concen trations of NOS2-specific inhibitor 1400W alone or in combination with HU. a) Immunocytochemistry for Ki67 protein and quantification of Ki67-positive cells as a proliferation marker. b) Cell cycle analysis by flow cytometry. Debris and doublets were excluded, and the distribution in the phases of the cell cycle was determined based on the incorporation of PI. c) Percentage of cells in G0/G1, S, or G2/M phases of the cell cycle was quantified. d) Gating of NOS2kd HEL92.1.7 cells based on GFP expression. e) Quantification of NOS1-, NOS2-, or NOS3-positive cells in NOS2kd and control HEL92.1.7 cells after immunocytochemistry. f) Immunocyto chemistry for Ki67 protein in NOS2kd or control HEL92.1.7 cells treated or not with HU, and quantification of Ki67-positive cells. g) Example of gating for cell cycle distribution using PI by flow cytometry. Exclusion of debris, exclusion of doublets, distribution in G0/G1, S, or G2/M phases based on PI incorporation. h) Percentage of cells in G0/G1, S, or G2/M phases of the cell cycle in NOS2kd cells and controls treated or not with HU. n = 5; mean + SEM, *p < 0.05, **p < 0.01, ***p < 0.001 vs. Ctrl or as indicated.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Article Title: Hydroxyurea inhibits proliferation and stimulates apoptosis through inducible nitric oxide synthase in erythroid cells.

doi: 10.1016/j.biopha.2024.117723

Figure Lengend Snippet: Fig. 3. NOS2 inhibition or knockdown prevents HU-induced inhibition of HEL92.1.7 cell proliferation. HEL92.1.7 cells were treated with the indicated concen trations of NOS2-specific inhibitor 1400W alone or in combination with HU. a) Immunocytochemistry for Ki67 protein and quantification of Ki67-positive cells as a proliferation marker. b) Cell cycle analysis by flow cytometry. Debris and doublets were excluded, and the distribution in the phases of the cell cycle was determined based on the incorporation of PI. c) Percentage of cells in G0/G1, S, or G2/M phases of the cell cycle was quantified. d) Gating of NOS2kd HEL92.1.7 cells based on GFP expression. e) Quantification of NOS1-, NOS2-, or NOS3-positive cells in NOS2kd and control HEL92.1.7 cells after immunocytochemistry. f) Immunocyto chemistry for Ki67 protein in NOS2kd or control HEL92.1.7 cells treated or not with HU, and quantification of Ki67-positive cells. g) Example of gating for cell cycle distribution using PI by flow cytometry. Exclusion of debris, exclusion of doublets, distribution in G0/G1, S, or G2/M phases based on PI incorporation. h) Percentage of cells in G0/G1, S, or G2/M phases of the cell cycle in NOS2kd cells and controls treated or not with HU. n = 5; mean + SEM, *p < 0.05, **p < 0.01, ***p < 0.001 vs. Ctrl or as indicated.

Article Snippet: Membranes were incubated overnight at 4◦C with antibodies against phospho-NOS2 (Tyr151) (TA325739, OriGene, Rockville, Maryland, USA), NOS2 (E-AB-64331, Elabscience, Houston, Texas, USA), phosphorylated NFκB p65 (p-NFκB p65) (Ser536) (3031, Cell Signaling, Danvers, Massachusetts, USA), total NFκB p65 (E-AB-22066, Elabscience), phospho-p38 (Tyr180/Tyr182) (E-AB-21027, Elabscience), total p38 (E-AB-66279, Elabscience), phospho-p44/42 (extracellular signal-regulated kinase 1⁄2 [Erk1/2]) (Thr202/Tyr204) (9101, Cell Signaling), total p44/42 (Erk1/2) (9102, Cell Signaling), or β-actin (MAB8928, R&D Systems, Minneapolis, Minnesota, USA).

Techniques: Inhibition, Knockdown, Immunocytochemistry, Marker, Cell Cycle Assay, Flow Cytometry, Expressing, Control

Fig. 4. NOS2 inhibition or knockdown prevents HU-induced apoptosis in HEL92.1.7 cells. HEL92.1.7 cells were treated with the indicated concentrations of NOS2- specific inhibitor 1400W alone or in combination with HU. a) Immunocytochemistry for ssDNA and quantification of ssDNA-positive cells. b) Example of gating for the apoptotic assay by flow cytometry. The bottom left quadrant represents early apoptotic cells, and the upper left quadrant represents late apoptotic cells. c) Percentage of early apoptotic cells. d) Percentage of late apoptotic cells. e) Immunocytochemistry for ssDNA on NOS2kd or control HEL92.1.7 cells treated or not with HU and quantification of ssDNA-positive cells. f) Example of gating for the apoptotic assay by flow cytometry with numbers of early and late apoptotic cells. g) Percentage of early and late apoptotic cells. n = 5; mean + SEM, *p < 0.05, **p < 0.01, ***p < 0.001 vs. Ctrl or as indicated.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Article Title: Hydroxyurea inhibits proliferation and stimulates apoptosis through inducible nitric oxide synthase in erythroid cells.

doi: 10.1016/j.biopha.2024.117723

Figure Lengend Snippet: Fig. 4. NOS2 inhibition or knockdown prevents HU-induced apoptosis in HEL92.1.7 cells. HEL92.1.7 cells were treated with the indicated concentrations of NOS2- specific inhibitor 1400W alone or in combination with HU. a) Immunocytochemistry for ssDNA and quantification of ssDNA-positive cells. b) Example of gating for the apoptotic assay by flow cytometry. The bottom left quadrant represents early apoptotic cells, and the upper left quadrant represents late apoptotic cells. c) Percentage of early apoptotic cells. d) Percentage of late apoptotic cells. e) Immunocytochemistry for ssDNA on NOS2kd or control HEL92.1.7 cells treated or not with HU and quantification of ssDNA-positive cells. f) Example of gating for the apoptotic assay by flow cytometry with numbers of early and late apoptotic cells. g) Percentage of early and late apoptotic cells. n = 5; mean + SEM, *p < 0.05, **p < 0.01, ***p < 0.001 vs. Ctrl or as indicated.

Article Snippet: Membranes were incubated overnight at 4◦C with antibodies against phospho-NOS2 (Tyr151) (TA325739, OriGene, Rockville, Maryland, USA), NOS2 (E-AB-64331, Elabscience, Houston, Texas, USA), phosphorylated NFκB p65 (p-NFκB p65) (Ser536) (3031, Cell Signaling, Danvers, Massachusetts, USA), total NFκB p65 (E-AB-22066, Elabscience), phospho-p38 (Tyr180/Tyr182) (E-AB-21027, Elabscience), total p38 (E-AB-66279, Elabscience), phospho-p44/42 (extracellular signal-regulated kinase 1⁄2 [Erk1/2]) (Thr202/Tyr204) (9101, Cell Signaling), total p44/42 (Erk1/2) (9102, Cell Signaling), or β-actin (MAB8928, R&D Systems, Minneapolis, Minnesota, USA).

Techniques: Inhibition, Knockdown, Immunocytochemistry, Flow Cytometry, Control

Fig. 5. In vivo HU treatment of Nos2–/– mice impairs HU inhibition of proliferation in erythroid progenitors. a) Schematic representation of experimental setup: Nos2–/– or wild-type (WT) mice were treated orally with 200 mg/kg HU or drinking water for 2 weeks. WT mice were injected with 20 mg/kg of 1400W twice daily for 3 consecutive days. Mouse erythroid progenitors (mERP) were isolated from bone marrow by immunomagnetic cell separation using anti-CD71-PE and anti- Ter119-FITC antibodies. b) Immunocytochemistry for Nos2 protein in mERP isolated from WT mice treated or not with HU. Quantification of Nos2-positive cells. c) Citrulline concentration in the bone marrow of WT and Nos2–/– mice treated or not with HU. d) Colony formation assay showing the number of late erythroid (CFU-E), early erythroid (BFU-E), or granulocyte/macrophage progenitors (CFU-GM) in the bone marrow of WT or Nos2–/– mice treated or not with HU. e) Immunocytochemistry for Ki67 in mERP cells isolated from WT and Nos2–/– mice treated or not with HU. f) Quantification of Ki67-positive cells. g) Cell cycle distribution by flow cytometry showing the percentage of cells in G0/G1, S, or G2/M phases of the cell cycle. c) n = 3, f) n = 5; mean + SEM, *p < 0.05, **p < 0.01, ***p < 0.001 vs. WT.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Article Title: Hydroxyurea inhibits proliferation and stimulates apoptosis through inducible nitric oxide synthase in erythroid cells.

doi: 10.1016/j.biopha.2024.117723

Figure Lengend Snippet: Fig. 5. In vivo HU treatment of Nos2–/– mice impairs HU inhibition of proliferation in erythroid progenitors. a) Schematic representation of experimental setup: Nos2–/– or wild-type (WT) mice were treated orally with 200 mg/kg HU or drinking water for 2 weeks. WT mice were injected with 20 mg/kg of 1400W twice daily for 3 consecutive days. Mouse erythroid progenitors (mERP) were isolated from bone marrow by immunomagnetic cell separation using anti-CD71-PE and anti- Ter119-FITC antibodies. b) Immunocytochemistry for Nos2 protein in mERP isolated from WT mice treated or not with HU. Quantification of Nos2-positive cells. c) Citrulline concentration in the bone marrow of WT and Nos2–/– mice treated or not with HU. d) Colony formation assay showing the number of late erythroid (CFU-E), early erythroid (BFU-E), or granulocyte/macrophage progenitors (CFU-GM) in the bone marrow of WT or Nos2–/– mice treated or not with HU. e) Immunocytochemistry for Ki67 in mERP cells isolated from WT and Nos2–/– mice treated or not with HU. f) Quantification of Ki67-positive cells. g) Cell cycle distribution by flow cytometry showing the percentage of cells in G0/G1, S, or G2/M phases of the cell cycle. c) n = 3, f) n = 5; mean + SEM, *p < 0.05, **p < 0.01, ***p < 0.001 vs. WT.

Article Snippet: Membranes were incubated overnight at 4◦C with antibodies against phospho-NOS2 (Tyr151) (TA325739, OriGene, Rockville, Maryland, USA), NOS2 (E-AB-64331, Elabscience, Houston, Texas, USA), phosphorylated NFκB p65 (p-NFκB p65) (Ser536) (3031, Cell Signaling, Danvers, Massachusetts, USA), total NFκB p65 (E-AB-22066, Elabscience), phospho-p38 (Tyr180/Tyr182) (E-AB-21027, Elabscience), total p38 (E-AB-66279, Elabscience), phospho-p44/42 (extracellular signal-regulated kinase 1⁄2 [Erk1/2]) (Thr202/Tyr204) (9101, Cell Signaling), total p44/42 (Erk1/2) (9102, Cell Signaling), or β-actin (MAB8928, R&D Systems, Minneapolis, Minnesota, USA).

Techniques: In Vivo, Inhibition, Injection, Isolation, Immunocytochemistry, Concentration Assay, Colony Assay, Flow Cytometry

Fig. 6. In vivo HU treatment of Nos2–/– mice impairs HU stimulation of apoptosis in erythroid progenitors. a) Immunocytochemistry for Cas3 in mouse erythroid progenitors (mERP) after treatment of WT or Nos2–/– mice with 1400W and/or HU. b) Quantification of Cas3-positive mERP. c) Example of gating for Annexin V/PI apoptotic assay by flow cytometry with numbers of early and late apoptotic mERP cells. d) Percentage of early apoptotic mERP cells. e) Percentage of late apoptotic mERP cells. f) Percentage of total apoptotic mERP cells. n = 5; mean + SEM, *p < 0.05, **p < 0.01, ***p < 0.001 vs. WT.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Article Title: Hydroxyurea inhibits proliferation and stimulates apoptosis through inducible nitric oxide synthase in erythroid cells.

doi: 10.1016/j.biopha.2024.117723

Figure Lengend Snippet: Fig. 6. In vivo HU treatment of Nos2–/– mice impairs HU stimulation of apoptosis in erythroid progenitors. a) Immunocytochemistry for Cas3 in mouse erythroid progenitors (mERP) after treatment of WT or Nos2–/– mice with 1400W and/or HU. b) Quantification of Cas3-positive mERP. c) Example of gating for Annexin V/PI apoptotic assay by flow cytometry with numbers of early and late apoptotic mERP cells. d) Percentage of early apoptotic mERP cells. e) Percentage of late apoptotic mERP cells. f) Percentage of total apoptotic mERP cells. n = 5; mean + SEM, *p < 0.05, **p < 0.01, ***p < 0.001 vs. WT.

Article Snippet: Membranes were incubated overnight at 4◦C with antibodies against phospho-NOS2 (Tyr151) (TA325739, OriGene, Rockville, Maryland, USA), NOS2 (E-AB-64331, Elabscience, Houston, Texas, USA), phosphorylated NFκB p65 (p-NFκB p65) (Ser536) (3031, Cell Signaling, Danvers, Massachusetts, USA), total NFκB p65 (E-AB-22066, Elabscience), phospho-p38 (Tyr180/Tyr182) (E-AB-21027, Elabscience), total p38 (E-AB-66279, Elabscience), phospho-p44/42 (extracellular signal-regulated kinase 1⁄2 [Erk1/2]) (Thr202/Tyr204) (9101, Cell Signaling), total p44/42 (Erk1/2) (9102, Cell Signaling), or β-actin (MAB8928, R&D Systems, Minneapolis, Minnesota, USA).

Techniques: In Vivo, Immunocytochemistry, Flow Cytometry

Histological and immunohistochemical analyses of the synovium. ( A ) Hematoxylin and Eosin staining. Images were taken at 100×. ( B ) Immunohistochemistry results for iNOS and CD206. ( C ) Immunohistochemistry results for IL-1β. Graphs show the results of the synovial lining cell layer and the ratio of the positive cells to the total cells for each protein at four and eight weeks after transplantation. Asterisk indicates a statistically significant difference. Grading of enlargement of the synovial lining cell layer was based on the method of previous report . Scale bars = 100 µm.

Journal: Journal of Clinical Medicine

Article Title: Attenuation of Knee Osteoarthritis Progression in Mice through Polarization of M2 Macrophages by Intra-Articular Transplantation of Non-Cultured Human Adipose-Derived Regenerative Cells

doi: 10.3390/jcm10194309

Figure Lengend Snippet: Histological and immunohistochemical analyses of the synovium. ( A ) Hematoxylin and Eosin staining. Images were taken at 100×. ( B ) Immunohistochemistry results for iNOS and CD206. ( C ) Immunohistochemistry results for IL-1β. Graphs show the results of the synovial lining cell layer and the ratio of the positive cells to the total cells for each protein at four and eight weeks after transplantation. Asterisk indicates a statistically significant difference. Grading of enlargement of the synovial lining cell layer was based on the method of previous report . Scale bars = 100 µm.

Article Snippet: After washing with PBS and formalin fixation, the cells on the slides were incubated with the conjugated primary antibodies iNOS (1:100, bs-2072R-FITC, Bioss, Woburn, MA, USA) and CD206 (1:100, bs4727R-Cy5.5, Bioss) for 3 h at 37 °C.

Techniques: Immunohistochemical staining, Staining, Immunohistochemistry, Transplantation Assay

Immunocyto-fluorescent analysis of the effect on the macrophages by co-culture assay with ADRCs. Representative images showed immunofluorescent staining for the macrophage marker iNOS (green) and CD206 (red). Scale bars = 100 μm. Graphs show the ratio of the number of positive cells to the number of DAPI-positive cells for iNOS and CD206. * p < 0.05, ** p < 0.01.

Journal: Journal of Clinical Medicine

Article Title: Attenuation of Knee Osteoarthritis Progression in Mice through Polarization of M2 Macrophages by Intra-Articular Transplantation of Non-Cultured Human Adipose-Derived Regenerative Cells

doi: 10.3390/jcm10194309

Figure Lengend Snippet: Immunocyto-fluorescent analysis of the effect on the macrophages by co-culture assay with ADRCs. Representative images showed immunofluorescent staining for the macrophage marker iNOS (green) and CD206 (red). Scale bars = 100 μm. Graphs show the ratio of the number of positive cells to the number of DAPI-positive cells for iNOS and CD206. * p < 0.05, ** p < 0.01.

Article Snippet: After washing with PBS and formalin fixation, the cells on the slides were incubated with the conjugated primary antibodies iNOS (1:100, bs-2072R-FITC, Bioss, Woburn, MA, USA) and CD206 (1:100, bs4727R-Cy5.5, Bioss) for 3 h at 37 °C.

Techniques: Co-culture Assay, Staining, Marker